Motif Bio’s (LON:MTFB) Buy Rating Reaffirmed at Northland Securities

Northland Securities restated their buy rating on shares of Motif Bio (LON:MTFB) in a research report sent to investors on Monday, February 5th.

MTFB has been the subject of several other reports. FinnCap reissued a buy rating and issued a GBX 100 ($1.38) target price on shares of Motif Bio in a report on Wednesday, November 22nd. Peel Hunt reissued a buy rating on shares of Motif Bio in a report on Friday, December 22nd. Finally, Beaufort Securities reaffirmed a speculative buy rating and set a GBX 110 ($1.52) price objective on shares of Motif Bio in a report on Thursday, November 16th.

Shares of Motif Bio (LON:MTFB) opened at GBX 34 ($0.47) on Monday. The stock has a market cap of $90.81 and a P/E ratio of -130.77. Motif Bio has a fifty-two week low of GBX 22.50 ($0.31) and a fifty-two week high of GBX 51.75 ($0.71).

WARNING: “Motif Bio’s (LON:MTFB) Buy Rating Reaffirmed at Northland Securities” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/13/motif-bios-mtfb-buy-rating-reaffirmed-at-northland-securities-2.html.

About Motif Bio

Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).

Receive News & Ratings for Motif Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply